Extended Data Table 3 Patient transplantation course over full study period

From: Irradiation- and busulfan-free stem cell transplantation in Fanconi anemia using an anti-CD117 antibody: a phase 1b trial

  1. All patients were treated without developing investigational product severe adverse events (SAEs) to either briquilimab or αβdepleted-HSPC grafts (n = 3). No VOD was observed with expected grade 2-3 mucositis in all patients. Typical viral reactivations were observed post-HSCT with minimal GvHD despite use of haploidentical mobilized peripheral blood donor grafts.
Back to article page